TY - JOUR
T1 - Serum levels of interleukin-33 and its soluble form receptor (sST2) are associated with cognitive performance in patients with schizophrenia
AU - de Campos-Carli, Salvina Maria
AU - Miranda, Aline Silva
AU - Dias, Ingrid Caroline Silva
AU - de Oliveira, Amanda
AU - Cruz, Breno Fiuza
AU - Vieira, Érica Leandro Marciano
AU - Rocha, Natalia Pessoa
AU - Barbosa, Izabela Guimarães
AU - Salgado, João Vinícius
AU - Teixeira, Antônio Lúcio
N1 - Publisher Copyright:
© 2017 Elsevier Inc.
PY - 2017/4/1
Y1 - 2017/4/1
N2 - Objective Changes in immune system have been reported in schizophrenia. This study aimed to evaluate the involvement of IL-33, a member of the IL-1 cytokine family, in schizophrenia and its association with cognitive performance in these patients. Methods Forty patients with chronic schizophrenia and 40 healthy subjects participated in the study. Serum levels of IL-33 and sST2 (soluble form of the IL-33 receptor) were measured using enzyme-linked immunosorbent assay (ELISA). Patients were evaluated with the Brief Assessment of Cognition in Schizophrenia (BACS) and the Schizophrenia Cognition Rating Scale (SCoRS). Results Patients with schizophrenia and controls presented similar serum levels of IL-33 and sST2. Levels of both markers were positively correlated with cognitive performance in patients with schizophrenia. Conclusion We found a significant correlation between IL-33 and sST2 levels and cognition in schizophrenia. Our results might help in the understanding of how immune markers are associated with cognitive impairment in schizophrenia. It remains to be determined whether the association between IL-33/sST2 and cognition is restricted to patients with schizophrenia.
AB - Objective Changes in immune system have been reported in schizophrenia. This study aimed to evaluate the involvement of IL-33, a member of the IL-1 cytokine family, in schizophrenia and its association with cognitive performance in these patients. Methods Forty patients with chronic schizophrenia and 40 healthy subjects participated in the study. Serum levels of IL-33 and sST2 (soluble form of the IL-33 receptor) were measured using enzyme-linked immunosorbent assay (ELISA). Patients were evaluated with the Brief Assessment of Cognition in Schizophrenia (BACS) and the Schizophrenia Cognition Rating Scale (SCoRS). Results Patients with schizophrenia and controls presented similar serum levels of IL-33 and sST2. Levels of both markers were positively correlated with cognitive performance in patients with schizophrenia. Conclusion We found a significant correlation between IL-33 and sST2 levels and cognition in schizophrenia. Our results might help in the understanding of how immune markers are associated with cognitive impairment in schizophrenia. It remains to be determined whether the association between IL-33/sST2 and cognition is restricted to patients with schizophrenia.
UR - http://www.scopus.com/inward/record.url?scp=85009926989&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85009926989&partnerID=8YFLogxK
U2 - 10.1016/j.comppsych.2017.01.008
DO - 10.1016/j.comppsych.2017.01.008
M3 - Article
C2 - 28126482
AN - SCOPUS:85009926989
SN - 0010-440X
VL - 74
SP - 96
EP - 101
JO - Comprehensive Psychiatry
JF - Comprehensive Psychiatry
ER -